Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Intergenic disease-associated regions are abundant in novel transcripts.

Bartonicek N, Clark MB, Quek XC, Torpy JR, Pritchard AL, Maag JLV, Gloss BS, Crawford J, Taft RJ, Hayward NK, Montgomery GW, Mattick JS, Mercer TR, Dinger ME.

Genome Biol. 2017 Dec 28;18(1):241. doi: 10.1186/s13059-017-1363-3.

2.

Machine learning annotation of human branchpoints.

Signal B, Gloss BS, Dinger ME, Mercer TR.

Bioinformatics. 2018 Mar 15;34(6):920-927. doi: 10.1093/bioinformatics/btx688.

PMID:
29092009
3.

Long Noncoding RNAs CUPID1 and CUPID2 Mediate Breast Cancer Risk at 11q13 by Modulating the Response to DNA Damage.

Betts JA, Moradi Marjaneh M, Al-Ejeh F, Lim YC, Shi W, Sivakumaran H, Tropée R, Patch AM, Clark MB, Bartonicek N, Wiegmans AP, Hillman KM, Kaufmann S, Bain AL, Gloss BS, Crawford J, Kazakoff S, Wani S, Wen SW, Day B, Möller A, Cloonan N, Pearson J, Brown MA, Mercer TR, Waddell N, Khanna KK, Dray E, Dinger ME, Edwards SL, French JD.

Am J Hum Genet. 2017 Aug 3;101(2):255-266. doi: 10.1016/j.ajhg.2017.07.007.

4.

High resolution temporal transcriptomics of mouse embryoid body development reveals complex expression dynamics of coding and noncoding loci.

Gloss BS, Signal B, Cheetham SW, Gruhl F, Kaczorowski DC, Perkins AC, Dinger ME.

Sci Rep. 2017 Jul 27;7(1):6731. doi: 10.1038/s41598-017-06110-5.

5.

Computational Approaches for Functional Prediction and Characterisation of Long Noncoding RNAs.

Signal B, Gloss BS, Dinger ME.

Trends Genet. 2016 Oct;32(10):620-637. doi: 10.1016/j.tig.2016.08.004. Epub 2016 Sep 1. Review.

PMID:
27592414
6.

Unexpected features of the dark proteome.

Perdigão N, Heinrich J, Stolte C, Sabir KS, Buckley MJ, Tabor B, Signal B, Gloss BS, Hammang CJ, Rost B, Schafferhans A, O'Donoghue SI.

Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15898-903. doi: 10.1073/pnas.1508380112. Epub 2015 Nov 17.

7.

Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.

Moran-Jones K, Gloss BS, Murali R, Chang DK, Colvin EK, Jones MD, Yuen S, Howell VM, Brown LM, Wong CW, Spong SM, Scarlett CJ, Hacker NF, Ghosh S, Mok SC, Birrer MJ, Samimi G.

Oncotarget. 2015 Dec 29;6(42):44551-62. doi: 10.18632/oncotarget.6082.

8.

The specificity of long noncoding RNA expression.

Gloss BS, Dinger ME.

Biochim Biophys Acta. 2016 Jan;1859(1):16-22. doi: 10.1016/j.bbagrm.2015.08.005. Epub 2015 Aug 19. Review.

PMID:
26297315
9.

Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells.

Rogers S, Gloss BS, Lee CS, Sergio CM, Dinger ME, Musgrove EA, Burgess A, Caldon CE.

Cell Div. 2015 Feb 19;10:1. doi: 10.1186/s13008-015-0007-9. eCollection 2015.

10.

lncRNAdb v2.0: expanding the reference database for functional long noncoding RNAs.

Quek XC, Thomson DW, Maag JL, Bartonicek N, Signal B, Clark MB, Gloss BS, Dinger ME.

Nucleic Acids Res. 2015 Jan;43(Database issue):D168-73. doi: 10.1093/nar/gku988. Epub 2014 Oct 20.

11.

Epigenetic biomarkers in epithelial ovarian cancer.

Gloss BS, Samimi G.

Cancer Lett. 2014 Jan 28;342(2):257-63. doi: 10.1016/j.canlet.2011.12.036. Epub 2012 Jan 12. Review.

PMID:
22245949
12.

Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers.

Gloss BS, Patterson KI, Barton CA, Gonzalez M, Scurry JP, Hacker NF, Sutherland RL, O'Brien PM, Clark SJ.

Cancer Lett. 2012 May 1;318(1):76-85. doi: 10.1016/j.canlet.2011.12.003. Epub 2011 Dec 9.

PMID:
22155104
13.

Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.

Montavon C, Gloss BS, Warton K, Barton CA, Statham AL, Scurry JP, Tabor B, Nguyen TV, Qu W, Samimi G, Hacker NF, Sutherland RL, Clark SJ, O'Brien PM.

Gynecol Oncol. 2012 Mar;124(3):582-8. doi: 10.1016/j.ygyno.2011.11.026. Epub 2011 Nov 22.

PMID:
22115852
14.

MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.

Byrne JA, Maleki S, Hardy JR, Gloss BS, Murali R, Scurry JP, Fanayan S, Emmanuel C, Hacker NF, Sutherland RL, Defazio A, O'Brien PM.

BMC Cancer. 2010 Sep 17;10:497. doi: 10.1186/1471-2407-10-497.

15.

Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival.

Barton CA, Gloss BS, Qu W, Statham AL, Hacker NF, Sutherland RL, Clark SJ, O'Brien PM.

Br J Cancer. 2010 Jan 5;102(1):87-96. doi: 10.1038/sj.bjc.6605429. Epub 2009 Nov 24.

16.

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.

O'Brien PM, Davies MJ, Scurry JP, Smith AN, Barton CA, Henderson MJ, Saunders DN, Gloss BS, Patterson KI, Clancy JL, Heinzelmann-Schwarz VA, Murali R, Scolyer RA, Zeng Y, Williams ED, Scurr L, Defazio A, Quinn DI, Watts CK, Hacker NF, Henshall SM, Sutherland RL.

Br J Cancer. 2008 Mar 25;98(6):1085-93. doi: 10.1038/sj.bjc.6604281. Epub 2008 Mar 18. Erratum in: Br J Cancer. 2008 Jun 3;98(11):1880. Murali, Rajmohan [added].

Supplemental Content

Loading ...
Support Center